ZYME Zymeworks Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZYME

Price (delayed)

$22.86

Market cap

$1.67B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.37

Enterprise value

$1.69B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 38

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of ...

Highlights
The quick ratio has surged by 133% year-on-year and by 88% since the previous quarter
ZYME's EPS is down by 27% since the previous quarter but it is up by 9% year-on-year
Zymeworks's net income has decreased by 27% QoQ but it has increased by 10% YoY
The company's equity fell by 50% YoY and by 39% QoQ
Zymeworks's revenue has decreased by 23% from the previous quarter and by 13% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zymeworks.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ZYME

ZYME stock price

How has the Zymeworks stock price performed over time
Intraday
-1.12%
1 week
-5.5%
1 month
-5.93%
1 year
63.17%
YTD
-13.18%
QTD
-12.55%

Financial performance

How have Zymeworks's revenue and profit performed over time
Revenue
$81.26M
Gross profit
$81.26M
Operating income
-$114.05M
Net income
-$102.66M
Gross margin
100%
Net margin
-126.3%
The company's net margin has shrunk by 65% QoQ and by 3.8% YoY
The operating margin has plunged by 61% from the previous quarter and by 4.9% YoY
Zymeworks's net income has decreased by 27% QoQ but it has increased by 10% YoY
ZYME's operating income is down by 23% since the previous quarter but it is up by 9% year-on-year

Price vs fundamentals

How does ZYME's price correlate with its fundamentals

Growth

What is Zymeworks's growth rate over time

Valuation

What is Zymeworks stock price valuation
ZYME P/E details
P/E
N/A
P/B
10.31
P/S
21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.78
ZYME's EPS is down by 27% since the previous quarter but it is up by 9% year-on-year
ZYME's P/B is 64% above its last 4 quarters average of 6.3
The company's equity fell by 50% YoY and by 39% QoQ
The stock's price to sales (P/S) is 44% more than its 5-year quarterly average of 14.6 and 42% more than its last 4 quarters average of 14.8
Zymeworks's revenue has decreased by 23% from the previous quarter and by 13% YoY

Efficiency

How efficient is Zymeworks business performance
ZYME's ROS has dropped by 67% since the previous quarter and by 9% year-on-year
Zymeworks's return on equity has decreased by 45% QoQ and by 20% YoY
Zymeworks's ROA has decreased by 22% from the previous quarter and by 5% YoY
ZYME's ROIC is down by 12% since the previous quarter but it is up by 6% year-on-year

Dividends

What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZYME.

Financial health

How did Zymeworks financials performed over time
Zymeworks's total assets is 52% higher than its total liabilities
The quick ratio has surged by 133% year-on-year and by 88% since the previous quarter
The company's current ratio has surged by 130% YoY and by 84% QoQ
The company's debt is 61% higher than its equity
The company's equity fell by 50% YoY and by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.